EMPA-KIDNEY® Kids Trial
Phase 3
120
about 3.5 years
2–17
30 sites in AL, AZ, CA +20
About this study
This trial is testing empagliflozin in children and adolescents with chronic kidney disease (CKD). The goal is to determine if empagliflozin helps these patients and how well they tolerate the medication. Participants will take either empagliflozin or a placebo for over a year.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Empagliflozin
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
oral (Oral Tablet)
Primary: Change from Day 1 to the Week 24 visit in urine albumin-creatinine (UACR) [mg/g]
Secondary: Annual rate of change in eGFR (U25Crea) from the Week 8 to the Week 24 visit, including treatment effect extrapolation from (adult) EMPA-KIDNEY data, Change from Day 1 to the Week 24 visit in urine protein-creatinine ratio (UPCR), Change in estimated glomerular filtration rate (eGFR) (U25Crea) over time during treatment with empagliflozin, Occurrence of at least one SAE or AE of special interest (AESI) per participant between Day 1 and the Week 24 visit, and between the Week 24 visit and end of treatment (EoT) +7 days residual effect period (REP)
Renal